This early-phase study tests whether combining low-dose steroids with the drug ruxolitinib can better control grade II acute graft-versus-host disease (aGVHD) after a stem cell transplant. About 30 participants with certain blood cancers will receive this combination as their fir…
Phase: PHASE1 • Sponsor: Daihong Liu • Aim: Disease control
Last updated May 11, 2026 20:51 UTC